<DOC>
	<DOCNO>NCT00357253</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Capecitabine may make tumor cell sensitive radiation therapy . Giving capecitabine together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose capecitabine give together radiation therapy treat young patient newly diagnose , nonmetastatic brain stem glioma high-grade glioma .</brief_summary>
	<brief_title>Capecitabine Radiation Therapy Treating Young Patients With Newly Diagnosed , Nonmetastatic Brain Stem Glioma High-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate maximum tolerate dose capecitabine rapidly disintegrate tablet ( RDT ) administer concurrently radiotherapy young patient newly diagnose , nondisseminated intrinsic brain stem glioma high-grade glioma . - Describe dose-limiting toxicity patient treated regimen . Secondary - Describe safety profile regimen . - Characterize pharmacokinetics capecitabine RDT patient . - Explore exposure-response relationship measure safety effectiveness use pharmacokinetic pharmacodynamic model . - Describe antitumor activity regimen observe patient . - Estimate distribution progression-free survival survival patient treat regimen . - Characterize radiographic change tumor , use MRI , perfusion diffusion MRI , positron emission tomography ( PET ) scan , patient treat regimen . OUTLINE : This multicenter , dose-escalation study capecitabine rapidly disintegrate tablet ( RDT ) . Patients undergo radiotherapy daily , 5 day week , approximately 6 week . Beginning within 24 hour start radiotherapy , patient also receive oral capecitabine RDT twice daily day 1-21 . Treatment capecitabine RDT repeat every 21 day 3 course . Cohorts 3-6 patient receive escalate dos capecitabine RDT maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Beginning week 12 , patient receive capecitabine RDT fix dose twice daily day 1-14 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients undergo blood collection periodically course 1 pharmacokinetic correlative study . Patients also undergo MRI , rapid perfusion/diffusion MRI baseline periodically study radiographic correlative study . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow newly diagnose , nondisseminated brain tumor : Intrinsic infiltrate brain stem glioma Histopathologic diagnosis require Histopathologically confirm highgrade glioma , meet follow criterion : Underwent prior definitive surgery ≤ 28 day ago incompletely resected disease Any follow subtypes allow : Anaplastic astrocytoma Glioblastoma multiforme Other highgrade glioma No anaplastic oligodendroglioma PATIENT CHARACTERISTICS : Karnofsky performance scale ( PS ) 50100 % ( &gt; 16 year age ) Lansky PS 50100 % ( ≤ 16 year age ) Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ ( transfusion independent ) Hemoglobin ≥ 8 g/dL ( transfusion independent ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine base age follow : No 0.8 mg/dL ( patient 5 year age ) No 1 mg/dL ( patient 610 year age ) No 1.2 mg/dL ( patient 1115 year age ) No 1.5 mg/dL ( patient 15 year age ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No significant cardiac , hepatic , gastrointestinal , renal , pulmonary , systemic disease No known hypersensitivity capecitabine components No known dihydropyrimidine dehydrogenase ( DPD ) deficiency PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior dexamethasone and/or surgery allow No prior chemotherapy , radiotherapy , immunotherapy , bone marrow transplantation No concurrent anticancer experimental drug therapy agents No concurrent warfarin sorivudine chemically related analogue ( e.g. , brivudine )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
</DOC>